Association of the Genetic Polymorphisms RRM1 −756T>C and −269C>A With Cervical Neoplasia

Abstract

Cervical neoplasia is one of the most prevalent malignant neoplasms worldwide. Ribonucleotide reductase 1 (RRM1) is thought to play an essential role in modulating the development and progression of cervical neoplasia. Two novel genetic polymorphisms, RRM1 −756T>C and −269 C>A, are significantly correlated with RRM1 expression. Some epidemiological studies have demonstrated that genetic variants play a crucial role in susceptibility to cervical cancer. The present study aimed to identify the genetic polymorphisms RRM1 −756T>C and −269 C>A in patients with cervical neoplasia and healthy controls. In total, 493 subjects, comprising 324 healthy controls and 169 patients with cervical neoplasia, were enrolled for this study. The allelic discrimination of the RRM1 −756T>C (rs11030918) and −269C>A (rs12806698) polymorphisms was assessed using the ABI StepOne™ real-time polymerase chain reaction system and analyzed using Software Design Specification (SDS), Version 3.0, software with TaqMan assays. The risk of cervical cancer was examined, revealing adjusted odds ratios and 95% confidence intervals of 1.25 [0.51, 3.08] and 1.09 [0.43, 2.78] for individuals with CC alleles of RRM1 −756T>C and for individuals with AA alleles of RRM1 −269C>A genetic polymorphisms, respectively, compared to individuals with wild-type RRM1 genetic polymorphisms. No significant genetic interaction effect was observed in susceptibility to cervical neoplasia, and no association was found between genetic polymorphisms and clinical statuses of invasive cervical cancer. The genetic polymorphisms RRM1 −756T>C and −269C>A may not be a factor for susceptibility to cervical neoplasia.

Keywords

ribonucleotide reductase 1 (RRM1)single nucleotide polymorphism (SNP)cervical neoplasia

Get full access to this article

View all access options for this article.

References

Bajpai

Banerjee

Pathak

Thakur

Jain

S. K.

Singh

(2016). Single nucleotide polymorphisms in the DNA repair genes in HPV-positive cervical cancer. European Journal of Cancer Prevention, 25, 224–231.

Bekkers

R. L.

Massuger

L. F.

Bulten

Melchers

W. J.

(2004). Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Reviews in Medical Virology, 14, 95–105.

Bennett

C. N.

Tomlinson

C. C.

Michalowski

A. M.

Chu

I. M.

Luger

Mittereder

L. R.

… Green

J. E.

(2012). Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Research, 14, R109.

Bepler

Zheng

Gautam

Sharma

Cantor

Sharma

… Haura

(2005). Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer, 47, 183–192.

Cao

Mitra

A. K.

Pounds

Crews

K. R.

Gandhi

Plunkett

… Lamba

J. K.

(2013). RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics, 14, 1449–1466.

Chen

D. R.

Chuang

C. Y.

B. C.

Yang

S. F.

Peng

Y. H.

Tsai

H. T.

(2014). Association of novel gene polymorphisms RRM1 -756t>C and -269 >A with breast cancer. Journal of Clinical Laboratory Analysis, 28, 287–293.

Chirenje

Z. M.

(2005). HIV and cancer of the cervix. Best Practice & Research: Clinical Obstetrics & Gynaecology, 19, 269–276.

Department of Health, Republic of China. (2013). Health statistics: II. Vital statistics. Taipei, Taiwan: Author.

Xiong

Wang

Shen

Peng

… Huang

(2014). The Thr241Met polymorphism in the XRCC3 gene is associated with increased risk of cancer in Chinese mainland populations. Tumour Biology, 35, 1371–1376.

10.

Fan

X. M.

K. X.

Niu

S. H.

Fang

Z. H.

Liu

(2013). [Relationship of XRCC1 polymorphism with the risks and clinicopathological factors of cervical cancer]. Zhonghua Yi Xue Za Zhi, 93, 3454–3456.

11.

Gautam

Bepler

(2006). Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Research, 66, 6497–6502.

12.

Hakansson

Hofer

Thelander

(2006). Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. Journal of Biological Chemistry, 281, 7834–7841.

13.

Jordheim

L. P.

Seve

Tredan

Dumontet

(2011). The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncology, 12, 693–702.

14.

Kunos

C. A.

Colussi

V. C.

Pink

Radivoyevitch

Oleinick

N. L.

(2011). Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: Enhanced radiation response at low-dose rates. International Journal of Radiation Oncology, Biology, Physics, 80, 1198–1204.

15.

Kunos

C. A.

Ferris

Pyatka

Pink

Radivoyevitch

(2011). Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers. Radiation Research, 176, 425–433.

16.

Kunos

C. A.

Radivoyevitch

Kresak

Dawson

Jacobberger

Yang

Abdul-Karim

F. W.

(2012). Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. International Journal of Gynecological Cancer, 22, 1463–1469.

17.

Kunos

C. A.

Radivoyevitch

Pink

Chiu

S. M.

Stefan

Jacobberger

Kinsella

T. J.

(2010). Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiation Research, 174, 574–581.

18.

Niida

Katsuno

Sengoku

Shimada

Yukawa

Ikura

… Nakanishi

(2010). Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase. Genes & Development, 24, 333–338.

19.

Ostor

A. G.

(1993). Studies on 200 cases of early squamous cell carcinoma of the cervix. International Journal of Gynecological Pathology, 12, 193–207.

20.

Reid

Wallant

N. C.

Patel

Antonic

Saxon-Aliifaalogo

Cao

… Watson

D. (2009). Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. Journal of RNAi and Gene Silencing, 5, 321–330.

21.

Rodriguez

Boni

Hernandez

Bitarte

Zarate

Ponz-Sarvise

… Garcia-Foncillas

(2011). Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. European Journal of Cancer, 47, 839–847.

22.

Ryu

J. S.

Shin

E. S.

Nam

H. S.

H. G.

Cho

J. H.

Kim

C. S.

… Lee

J. E.

(2011). Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. Journal of Thoracic Oncology, 6, 1320–1329.

23.

Soo

R. A.

Wang

L. Z.

S. S.

Chong

P. Y.

Yong

W. P.

Lee

S. C.

… Soong

(2009). Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung Cancer, 63, 121–127.

24.

Tsai

H. T.

Tsai

Y. M.

Yang

S. F.

Lee

C. H.

Lin

L. Y.

Lee

M. T.

(2009). A notable accessory screening program for detection of cervical intraepithelial neoplasia. Pathologie Biologie, 57, 477–482.

25.

Tsai

H. T.

Tsai

Y. M.

Yang

S. F.

K. Y.

Chuang

H. Y.

T. N.

… Wu

M. T.

(2007). Lifetime cigarette smoke and second-hand smoke and cervical intraepithelial neoplasm—A community-based case–control study. Gynecologic Oncology, 105, 181–188.

26.

Tsai

H. T.

C. H.

Lai

H. L.

R. N.

Tung

Y. C.

Chuang

H. Y.

… Wu

M. T.

(2005). Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiology, Biomarkers & Prevention, 14, 2544–2549.

27.

Zhang

Y. W.

Jones

T. L.

Martin

S. E.

Caplen

N. J.

Pommier

(2009). Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. Journal of Biological Chemistry, 284, 18085–18095.